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In Brief
It is well known that immunoglobulin G
N-glycosylation is required for
recognition by immune cell receptors;
however, it is not clear why. Subedi and
Barb demonstrate that N-glycosylation
stabilizes a single small protein loop on
the Fc.
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Asparagine(N)297-linked glycosylation of immuno-
globulin G (IgG) Fc is required for binding to FcgRIIa,
IIb, and IIIa, although it is unclear how it contributes.
We found the quaternary structure of glycosylated Fc
was indistinguishable from aglycosylated Fc, indi-
cating that N-glycosylation does not maintain rela-
tive Fc Cg2/Cg3 domain orientation. However, the
conformation of the C0E loop, which contains N297,
was significantly perturbed in the aglycosylated
Fc variant. The conformation of the C0E loop as
measured with a range of Fc variants shows a strong
correlation with FcgRIIIa affinity. These results indi-
cate that the primary role of the IgG1 Fc N-glycan is
to stabilize the C0E loop through intramolecular inter-
actions between carbohydrate and amino acid resi-
dues, and preorganize the FcgRIIIa interface for
optimal binding affinity. The features that contribute
to the capacity of the IgG1 Fc N-glycan to restrict
protein conformation and tune binding affinity are
conserved in other antibodies including IgG2–IgG4,
IgD, IgE, and IgM.
INTRODUCTION
Antibodies form a specific bridge between pathogens and the
immune system to initiate a protective proinflammatory
response. Immunoglobulin G (IgG) is the most abundant
serum-borne antibody and can trigger multiple pathways,
including natural killer cell-mediated antibody-dependent
cellular cytotoxicity (ADCC) (Janeway et al., 2008). The speci-
ficity afforded by tight binding interactions through the IgG frag-
ment antigen binding (Fab) regions is leveraged by exogenous
therapeutic monoclonal antibodies (mAbs) used in the treatment
of a wide variety of diseases including cancer, autoimmune dis-
orders, and transplant rejection, to name a few (Adams and
Weiner, 2005; Chan and Carter, 2010; Scott et al., 2012; Singh
et al., 2009; Sliwkowski and Mellman, 2013). These protective
and curative effects largely require an intact IgG fragment crys-
tallizable (Fc) region for appropriate interaction with cell surface
Fc g receptors (FcgRs) (Bruhns et al., 2009; Jiang et al., 2011;
Nimmerjahn and Ravetch, 2008; Siberil et al., 2007). It is well
known that the co-translational modification of Fc with an aspar-Structure 23, 1573–15agine (N)-linked carbohydrate chain (glycan) is required for FcgR
interactions (Arnold et al., 2007; Jefferis et al., 1998; Mimura
et al., 2001; Nose and Wigzell, 1983), but it is not known why.
Appropriate N-glycosylation presents a significant barrier to
mAb manufacture because less expensive microbial expression
systems are incapable of appropriate N-glycosylation (Chadd
and Chamow, 2001; Jaffe et al., 2014; Roque et al., 2004; Se-
thuraman and Stadheim, 2006).
Certain structural features of Fc are well characterized. Fc is a
homodimer of the C-terminal half of the Ig g heavy-chain poly-
peptide. Fc forms a symmetric homodimer that is connected
through non-covalent interactions and disulfide bonds. Fc re-
tains full receptor binding properties once the Fab domains are
removed by proteolysis (Franklin, 1975; Nisonoff et al., 1960;
Porter, 1959). Each Fc heavy-chain monomer consists of an
N-terminal Cg2 domain that is linked by disulfide bonds in the
hinge region to the corresponding Cg2 domain of the dimer (Fig-
ure 1). Cg3 domains form a large non-covalent dimer interface,
further stabilizing the dimer conformation.
The Cg2 domains contain a single glycosylation site at N297,
which resides at the tip of the C0E loop (Figure 1). The Fc
N-glycan is primarily of a complex, biantennary type (Figure 1B)
with the predominant forms containing eight or more residues
(Mizuochi et al., 1982). Although N-glycosylation is required for
binding of the low affinity FcgRs (Jefferis, 2009; Lux et al.,
2013), the primary interface between Fc and FcgRIIIa is formed
by polypeptide contacts, and the receptor polypeptide does
not directly contact the Fc N-glycan (Sondermann et al., 2000).
It was likewise noted that changes to the N-glycan termini, distal
to the site of the intermolecular polypeptide contacts by >20 A˚,
affect FcgRIIIa affinity (Kaneko et al., 2006; Raju, 2008; Scallon
et al., 2007; Yamaguchi et al., 2006). Intermolecular glycan-
glycan contacts between Fc and the FcgR have been observed
by crystallography, but these are not required for binding and
involve only the first few Fc N-glycan residues (Ferrara et al.,
2011; Mizushima et al., 2011). FcgRIIIa binds Fc with a 1:1 stoi-
chiometry, breaking the symmetry of the Fc dimer and making
contact with the C0E loop of one Fc Cg2 domain (Figure 1).
Fc structures solved by X-ray crystallography, with few excep-
tions, show a largely similar Cg2 domain orientation (reviewed in
Frank et al., 2014). One hypothesis suggests the Fc N-glycan
affects FcgR binding by contributing to proper Cg2 domain
orientation, particularly with respect to galactose-terminated
and aglycosylated Fc (Borrok et al., 2012; Crispin et al., 2009;
Frank et al., 2014; Krapp et al., 2003; Sondermann, 2013). This
is supported by contacts of the N-glycans from each Cg2
domain at the Fc dimer symmetry axis, and indicates that83, September 1, 2015 ª2015 Elsevier Ltd All rights reserved 1573
Figure 1. Structure of the IgG1 Fc/FcgRIIIa
Complex
(A) The IgG1 Fc dimer (blue ribbon) binds to the
extracellular domain of FcgRIIIa (orange ribbon)
with high nanomolar affinity. A substantial contact
interface is formed by the C0E loop of one Fc chain
(highlighted in yellow) and the receptor poly-
peptide.
(B) The IgG Fc N-glycan, shown here in a cartoon
diagram according to the CfG convention (Varki,
2009), is required for FcgRIIIa binding. Numbers in
the cartoon shapes represent the numbering
strategy used to describe individual N-glycan
residues.
(C) The motion of the Fc N-glycan is restricted by
contacts with the polypeptide surface, including
F241, F243, and D265.removing the N-glycan would cause collapse of the Cg2 do-
mains, rendering Fc incapable of binding FcgRs. This hypothesis
was put in doubt by our recent report that Fc containing an
N-glycan trimmed back to a single GlcNAc residue still bound
FcgR with reasonable affinity because this Fc glycoform does
not contain enough residues tomake the glycan-glycan contacts
at the Fc dimer symmetry axis (Subedi et al., 2014). Furthermore,
this study established a link between N-glycan motion and
FcgRIIIa affinity.
The N-glycan was resolved in the first Fc structure solved
40 years ago (Huber et al., 1976). Based on this evidence, it
was long suggested that the N-glycan binds tightly to the Fc
polypeptide surface; however, significant motions of the
N-glycan termini were recently observed (Barb and Prestegard,
2011). This observation led to a new hypothesis stating that
the N-glycan influences FcgR affinity through motion whereby
a more mobile (less restricted) N-glycan is associated with
weaker FcgR affinity. Indeed, such a link was observed (Subedi
et al., 2014). However, these studies were not capable of
defining the mechanism by which the Fc N-glycan contributes
to FcgR affinity, or creating a new link between the structure of
a carbohydrate and activity of the protein to which it is attached.
Solution methods to characterize macromolecular structure
open new windows into the conformation and conformational
distribution sampled in a dilute medium (Ishima and Torchia,
2000; Lindorff-Larsen et al., 2005; Mertens and Svergun, 2010;
Mittermaier and Kay, 2006). Solution nuclear magnetic reso-
nance (NMR) spectroscopy excels with dynamic molecules or
moieties that resist crystallization. The timescales of Fc N-glycan
motion were described with these techniques (Barb and Preste-
gard, 2011). Extending NMR-based methods to measure the
orientation of domains or local structural elements is capable
of revealing conformations not visible in structures determined
by X-ray crystallography. NMR fails to solve complete, all-atom
structures with large molecules due to insufficient resolution of
each peak and because of signal-sapping, line-broadening
effects that scale withmoleculemass (Cavanagh et al., 2007; Tu-
garinov et al., 2004). However, targeted studies using selective
labeling can reveal molecular features not visible through any
other technique (Kato et al., 2010; Religa et al., 2010; Tugarinov1574 Structure 23, 1573–1583, September 1, 2015 ª2015 Elsevier Ltet al., 2006). By combining the best aspects of solution and solid-
state techniques we can characterize relationships between
structure and activity with high precision.
In this study, we evaluate the contribution of Fc N-glycosyla-
tion to Fc structure and FcgRIIIa affinity to determine how the
Fc N-glycan contributes to Fc activity and, in so doing, define
the mechanism behind a previously unknown role for N-glycans
in biology. We utilized two well-described Fc variants that are re-
ported to show no measurable affinity for FcgRIIIa: (glycosyl) Fc
D265A (Baudino et al., 2008; Bournazos et al., 2014; Clynes
et al., 2000; Lund et al., 1995, 1996) and (aglycosyl) Fc T299A
(Lazar et al., 2009; Sazinsky et al., 2008; Subedi et al., 2014).
Here, we report the identification of IgG1 Fc features that are sta-
bilized by N-glycosylation, and in the stabilized state contribute
to FcgRIIIa binding. These results are likewise informative of
human IgG2–IgG4, IgD, IgE, and IgM because the structural ele-
ments surrounding the IgG1 Fc N-glycan, including location and
potentially restricting residues, are conserved in these anti-
bodies (Subedi et al., 2014).
RESULTS
N-Glycosylation Effects on Fc Quaternary Structure
To probe the effects of glycosylation on Fc quaternary structure,
we first measured the relative orientation of the Fc Cg2 and Cg3
domains using solution NMR spectroscopy. Using selectively
15N-amino acid enriched HEK293F cell expression medium, we
recovered high yields (30–50 mg/l) of appropriately glycosylated
and 15N-labeled IgG1 Fc (see Figure S1). Sparse amino acid
labeling provides peak separation and supports measurement
of residual dipolar couplings (RDCs) to define the relative orien-
tation of each observable N-H bond vector (Prestegard et al.,
2014). If the structure of the individual Cg2 and Cg3 domains
in solution mirrors the conformation of available models, RDCs
can be interpreted to reveal the relative orientations of these
two domains with high precision.
RDCs from [15N-Y,K]-Fc wild-type (WT) were measured with
high precision (22 to +26 ± 1.5 Hz) and used to calculate align-
ment parameters from a range of Fc structures in the PDB deter-
mined using X-ray diffraction data (Berman et al., 2002). Fcd All rights reserved
Table 1. IgG1 Fc WT RDCs Fitted to PDB Models: Chain Aa
PDB:
Q Value from
Raw PDB
Q Value after Modeling PDB
Domain Orientation with Cg2
and Cg3 from 1L6X Reference Notes
1L6X 0.185 NAb DeLano et al., 2000 Fc + Z domain
2DTS 0.217 0.217 Matsumiya et al., 2007 afucosylated
4KU1 0.252 0.260 Frank et al., 2014 G2F
4BYH 0.270 0.226 Crispin et al., 2013 disialyl
2WAH 0.306 0.295 Crispin et al., 2009 M9N2
3AVE 0.306 0.218 Matsumiya et al., 2007 fucosylated
3AY4 0.308 0.183 Mizushima et al., 2011 afucosylated Fc + FcgRIIIA
3DNK 0.355 0.210 unpublished data aglycosylated
3S7G 0.384 0.231 unpublished data aglycosylated
4Q6Y 0.397 0.268 Ahmed et al., 2014 disialyl
1H3T 0.404 0.221 Krapp et al., 2003 MN2F
1H3U 0.434 0.211 Krapp et al., 2003 M3N2F
4ACP 0.434 0.279 Baruah et al., 2012 EndoS treated
1E4K 0.438 0.207 Sondermann et al., 2000 Fc + FcgRIIIA
1H3X 0.463 0.220 Krapp et al., 2003 G0F
1H3Y 0.488 0.230 Krapp et al., 2003 high salt
3DO3 0.496 0.230 unpublished data
1H3V 0.537 0.220 Krapp et al., 2003 G2F, P212121
1FC1 0.542 0.207 Deisenhofer, 1981
1H3W 0.561 0.189 Krapp et al., 2003 G2F, C2221
3HKF 0.909 0.285 Feige et al., 2009 murine; aglycosylated
4CDH NDc 0.225 Silva-Martin et al., 2014 disialyl
The Q value in bold type calculated from 1L6X highlights the structure used for further comparison and structure refinement. Unpublished data are
available from http://www.rcsb.org.
aFits to other polypeptides in the structure files, where available, and provided similar results.
bNot applicable.
cNot determined; PALES failed to converge on a solution.behaves as symmetric dimer in solution, and a single peak for
each amino acid is observed even though two copies of the
polypeptide are present. The quality of fit to each structure
was quantified using a Q value (Cornilescu et al., 1998); Q values
range from 0 to 1 with optimal values %0.2. Of the structures
tested, 1L6X, generated using the highest-resolution Fc data
available (1.65 A˚ [DeLano et al., 2000]), fit to the RDC dataset
with Q = 0.185 which was lower than any other structure tested
(Tables 1 and S1). This result is notable because it indicates that
the 1L6X model closely represents the dominant orientation of
the individual Cg2 and Cg3 domains in solution and, thus, pro-
posed alternative conformations must be populated only mini-
mally (Frank et al., 2014). Q values represent changes in both
local structure (the precise N-H vector orientation, for example)
and global structure (relative domain orientations) and some
structures derived by X-ray crystallography have imprecise local
structural details. We eliminated the effect of local structural dif-
ferences in our analysis by individually fitting the domain orienta-
tion of each PDB using the well-resolved domains from 1L6X to
reveal a similar result, with only one model showing a slightly
lower Q (PDB: 3AY4, 0.183; Table 1). The Q value was improved
to a value of 0.170 by small rotations of the Cg2 domain relative
to the Cg3 domain.Structure 23, 1573–15RDCs reveal little difference between the predominant quater-
nary structures of an aglycosylated Fc variant in solution, Fc WT
in solution, and Fc WT in the crystal lattice. The Fc T299A variant
disrupts the N297-X-T299 Fc N-glycosylation sequon and is ex-
pressedwithout an N-glycan (Gavel and vonHeijne, 1990). RDCs
measured with Fc T299A were similar to Fc WT (R2 = 0.94) and
also fit well to 1L6X with Q = 0.177 (Table S1), which improved
to 0.170 by similar small rotations of the Cg2 domain. A compar-
ison of Cg2 orientations, shown in Figure 2, reveals the high
degree of similarity between the Cg2 orientations from crystal-
lography and NMR. Thus, the effect of glycosylation on Cg2
orientation is restricted to small amplitudes or small populations
not identified here. Based on these data, it appears that stabili-
zation of the Fc Cg2 domain orientation is not the predominant
contribution of N-glycosylation to FcgRIIIa binding.
N-Glycosylation Stabilizes the Fc C0 Strand andC0E Loop
Although the relative domain orientation appeared highly similar
in the Fc WT and Fc T299A samples, a few key differences
are found in 1H-15N heteronuclear single-quantum coherence-
transverse relaxation optimized spectroscopy (HSQC-TROSY)
spectra, as shown in Figures 3 and 4A. The majority of the peaks
corresponding to 15N-Y and 15N-K amide moieties do not83, September 1, 2015 ª2015 Elsevier Ltd All rights reserved 1575
Figure 2. NMR Indicates that Fc WT Cg2 Domain Orientation, Rela-
tive to the Cg3 Domain, Is Nearly Identical to that Observed by
X-Ray Crystallography and Changes Little upon Removing the
N-Glycan
(A) Orientations of the Cg2 domains are overlaid following optimization of the
Cg2 orientation, alignment of the Cg3 domains (not shown), and centering Cg2
domains by their centers of mass. The Fc model solved by X-ray crystallog-
raphy is shown as a blue ribbon. The orientations of Fc WT in solution (red
ribbon) and the non-glycosylated variant Fc T299A (green ribbon) are also
shown.
(B and C) Comparisons of the observed versus calculated RDCs for Fc WT (B)
and Fc T299A (C). The Fc N-glycan is not shown.change; however, Y300 shifts to a large extent in the Fc T299A
spectrum, and Y296, usually not observed in Fc WT, is observed
with Fc T299A. This is consistent with the observation of missing
density for Q295 and Y296 in a structure of aglycosylated Fc
solved by Georgiou and co-workers (Borrok et al., 2012). Two
other residues, K288 and K290, also shift and indicate significant
conformational rearrangement at these sites. The four residues
identified in this experiment are connected to the same second-
ary structural element: the C0E loop. Y300 and Y296 are closest1576 Structure 23, 1573–1583, September 1, 2015 ª2015 Elsevier Ltto the N297 site of N-glycosylation while K288 and K290 are
found further up the C0 strand that leads into the C0E loop
(Figure 3B).
The changes in amide crosspeak positions are mirrored by
changes in motion of the C0E loop. Solution NMR spectroscopy
offers the capability to probe macromolecular motion to atomic
detail by measuring rates of signal relaxation following 180
inversion (longitudinal relaxation, R1) or reorientation by 90

(transverse relaxation, R2) of the net nuclear magnetization
vector relative to the external magnetic field. These relaxation
rates are sensitive to motion as fast or faster than the 20-ns
Fc correlation time (R1 and R2) or motion in the microsecond
to millisecond timescale (R2 only) (Barb and Prestegard,
2011; Cavanagh et al., 2007). We observed no clear changes
in R1 relaxation rates for Fc secondary structural elements
by comparing rates measures with Fc WT and Fc T299A; how-
ever, the R2 relaxation rate for the Y300 amide
15N nucleus
was greater in the Fc T299A variant than in the Fc WT protein
(Figure 4B; Table S2). In total, these data indicate that the
C0E loop experiences an increase in the effect of relatively
slow microsecond to millisecond motion when the N-glycan
is absent. Significant differences observed in C0E loop and
C0 strand conformation and nuclear relaxation rates suggest
that the Fc N-glycan stabilizes the Fc structure and con-
tributes to FcgRIIIa binding by stabilizing local conformation
of the C0E loop, rather than by stabilizing global quaternary
structure.
C0E Loop Conformation Correlates with FcgRIIIa Affinity
To this point we identified local structural differences between Fc
with a complex-type N-glycan and aglycosylated Fc. We previ-
ously determined that Fc with a minimal N-glycan, consisting
of only a single GlcNAc residue attached at N297 (also referred
to as (1)GlcNAc-Fc WT), binds FcgRIIIa with a 10-fold reduction
in affinity when compared with Fc WT with a complex-type
N-glycan, as shown in Figure 5 (Subedi et al., 2014). This obser-
vation casts further doubt on the idea that the N-glycan orients
the Cg2 domains for optimal FcgRIIIa binding, because the
majority of the N-glycan, and the proposed N-glycan/N-glycan
contacts at the Fc dimer interface, cannot be formed in theFigure 3. A 1H-15N-HSQC-TROSY Spectrum
Reveals that N-Glycan Removal with a
T299A Mutation Perturbs Resonances in
the C0E Loop at Y296 and Y300 and along
the C0 Strand at K288 and K290
(A) These four resonances are found on the same
structural feature as the N297 glycosylation site.
(B) Y296 was not observed in spectra of glycosy-
lated Fc WT. Fc assignments were reported by
Kato and co-workers (Yagi et al., 2014).
d All rights reserved
Figure 4. NMR Measurements Indicate C0E Loop Structure and
Motion Is Stabilized on the Microsecond-Millisecond Timescale by
N297 Glycosylation
(A) Differences between peak positions of IgG1 Fc WT and the T299A variant
are plotted as described by Farmer et al. (1996).
(B and C) The differences between backbone amide nitrogen relaxation rates
from IgG1 Fc WT and the T299A variant measured using (B) R2 and (C) R1
experiments are shown. Error bars indicate the precision of measurement for
each set of relaxation rates (±1 SD). The dashed rectangle highlights obser-
vations from the C0E loop and C0 strand.(1)GlcNAc-Fc WT glycovariant (Baruah et al., 2012; Deisenhofer,
1981; Krapp et al., 2003; Sutton and Phillips, 1983). A published
structure of (1)GlcNAc-Fc does not show essential contacts be-
tween the (1)GlcNAc and polypeptide residues due to poor elec-
tron density of the C0E loop (Baruah et al., 2012), an unfortunate
result because the binding affinity of the (1)GlcNAc-Fc glycoform
is intermediate (5 mM) between Fc WT (0.5 mM) and Fc T299A
(>50 mM), and might highlight basic features of the Fc:FcgRIIIa
complex. Indeed, one striking structural difference is found inStructure 23, 1573–15an 1H-15N-HSQC-TROSY spectrum that revealed a large
displacement of the Y300 peak (Figure 5A).
The (1)GlcNAc residue shares a hydrophobic surface with the
V264 side chain and forms a hydrogen bond, through the acet-
amide moiety, with the D265 carboxylate (Figure 1C). If the
hydrogen bond is important for stabilizing the C0E loop through
the (1)GlcNAc residue, the D265A mutation should affect the
position of the Y300 1H-15N crosspeak. It is well known that Fc
D265A is glycosylated but fails to bind FcgRIIIa (Clynes et al.,
2000; Lund et al., 1995), consistent with our observation of
weak binding with KD >50 mM (Figures 5 and S2). An
1H-15N-
HSQC-TROSY spectrum reveals a significant shift of the Y300
peak in the D265A variant, further from that of the (1)GlcNAc-
Fc (Figure 5A). The assignment of the Y300 peak in the spectrum
of Fc D265A was confirmed through further mutation (Figures
5B–5D). The large shift of the Y300 crosspeak in Fc D265A is in-
dependent of glycoform (as characterized in Figures S1, S3, and
S4), indicating that the D265 coordination of the (1)GlcNAc res-
idue is crucial for maintaining the C0E loop in the conformation
observed with glycosylated Fc WT. Attempts to observe the
conformation of the C0E loop in the Fc:FcgRIIIa complex were
unsuccessful due to line-broadening relaxation, likely resulting
from intermediate kinetic exchange of the complex on the
NMR timescale (data not shown).
A line plotted through the overlaid Y300 peaks from WT and
D265A Fcs with various glycoforms traces an arc across the
spectra with substantial displacements in both dimensions
(4.5 ppm 15N, 0.35 ppm 1H). This large deviation indicates a
large conformational alteration in C0 strand and C0E loop
conformation, and interestingly, the Y300 chemical shift in both
the 15N and 1H dimensions correlates with FcgRIIIa affinity as
measured by surface plasmon resonance (R2 = 0.96 and 0.73;
respectively). This strong correlation supports the hypothesis
that the Fc N-glycan contributes to FcgRIIIa binding by
restricting C0E loop conformation through glycan-polypeptide
interactions.
Interactions between the (1)GlcNAc Residue and
Polypeptide Stabilize the N-Glycan
D265 stabilizes the N-glycan through a hydrogen bond with the
(1)GlcNAc residue; therefore, it is expected that a similar restric-
tionmay be observedwith peaks corresponding to N-glycan res-
idues. N-glycan residues can be specifically labeled by adding
13CU-glucose to the expression medium (Yamaguchi et al.,
1998). 1H-13C-HSQC spectra of 13C-labeled Fc show clear sig-
natures of N-glycan resonances and indicate that the majority
of the observed 13C labels are located in glycan residues, likely
due to the presence of amino acids in the serum-free expression
medium that inhibit metabolic scrambling of the labels (Figures
S5 and S6).
Anomeric 1H-13C correlations are valuable probes of N-glycan
structure because the resonance frequencies of these groups
are distinct from the other carbohydrate correlations. The
(1)-GlcNAc anomeric 1H1-13C1 crosspeak is found to be sepa-
rated from the remaining anomeric crosspeaks due to the unique
N-linkage. It is surprising that this moiety, in all FcWT glycoforms
analyzed, gives rise to two components. One minor peak is
observed with a resonance frequency of 5.1 ppm (1H), and
another predominant peak is observed at 5.0 ppm (1H), as83, September 1, 2015 ª2015 Elsevier Ltd All rights reserved 1577
Figure 5. The Peak Corresponding to Y300 Is Displaced in Spectra of Fc Variants
(A) 1H-15N HSQC-TROSY spectra of [15N-Y]-Fcs and FcgRIIIa affinity of Fc variants. The curved black arrow shows the direction of chemical shift change of the
Y300 peak with decreasing FcgRIIIa affinity.
(B–D) Assignment of the Y300 residue in the Fc D265A spectrum was performed by comparison with a spectrum of the Fc Y300F/D265A variant.shown in Figure 6. This peak duplication indicates a slow confor-
mational exchange of the atoms (on the NMR timescale) be-
tween two distinct chemical environments. Similar peak
duplication is also observed for peaks corresponding to the 2,
3, and 6 positions of the (1)GlcNAc residue (Figure S7). The dupli-
cated peaks collapse into a single crosspeak by either removing
all tertiary structure by Fc proteolysis, or by removing the
D265 carboxylate through amino acid substitution. The single
crosspeak overlaps with the less intense signal in the Fc WT
spectrum. This evidence indicates that a single environment of
the (1)GlcNAc is consistent with proper C0E loop conformation
and FcgRIIIa binding.
It is tempting to conclude that the two peaks observed for the
(1)GlcNAc residue of Fc WT correspond to two different confor-
mations of the N-glycan. This seems unlikely because the peak
intensity does not change upon altering the glycan composition,
and it is known that glycan extension stabilizes the N-glycan
(Barb, 2015; Barb et al., 2012). An alternative and potentially
more likely possibility is that the two (1)GlcNAc-Fc peaks result
from exchange of the nearby Y296 side chain between two
conformations, as was observed by Kato and co-workers (Mat-
sumiya et al., 2007). In either case, it is clear that multiple confor-
mations of the C0E loop are found in Fc WT, and the presence of
only the dominant conformation observed with Fc WT is consis-
tent with efficient FcgRIIIa binding.1578 Structure 23, 1573–1583, September 1, 2015 ª2015 Elsevier LtThe Behavior of the Fc D265A N-Glycan Termini Is
Similar to That of Fc WT
If D265 is required for coordinating the C0E loop by binding the
(1)GlcNAc residue, then we expect that removing the D265-
mediated interaction will disrupt N-glycan/polypeptide interac-
tions. F241 and F243 are known to contribute to N-glycan
restriction (Lund et al., 1996; Subedi et al., 2014), but the rela-
tive importance of each glycan/polypeptide interface to C0E
loop restriction and FcgRIIIa binding is unclear. Evidence sup-
porting a small disruption of the interface between N-glycan
and polypeptide residues is found in an analysis of the glycans
following expression of Fc D265A in the HEK293F cell line.
Mass spectrometric analysis of purified N-glycans revealed a
surprisingly small shift toward more highly modified glycoforms
when compared with the Fc WT protein (Table S3), and is
similar to mIgG2b Fc D265A (Baudino et al., 2008). However,
the degree of glycan remodeling is still far less than that
observed with other Fc variants. Fc F241S/F243S shows com-
plete disruption of the N-glycan-polypeptide interface and near
complete glycan processing in the Golgi, which is reflected in
the recovery of glycans with of high levels of galactose and
sialic acid incorporation and the appearance of tri-antennary
forms (Table S3; Subedi et al., 2014). The effects of N-glycan
heterogeneity are removed by enzymatic glycan remodeling
in vitro prior to structural and functional characterizationd All rights reserved
Figure 7. The D265A Fc Variant Retains Significant Contact between
the Polypeptide and N-Glycan Termini as Observed with the (6) and
(60) Galactose Residues
1H-13C HSQC spectra of (A) IgG1 Fc WT and (B) D265A variant. N-Glycans
were remodeled to display the G2F glycoform with 13C2-galactose. Positions
of FcWT peaks are highlighted by ‘‘+’’. Resonance frequencies consistent with
an exposed and unrestricted N-glycan are labeled ‘‘e’’ (Subedi et al., 2014).
Figure 6. The (1)GlcNAc Residue Experiences Multiple Chemical
Environments in FcWT, But only One State Is Present in Proteolyzed
Fc or Fc Variants that Bind FcgRIIIa Weakly, i.e. >50 mM
1H-13C HSQC spectra of 13C-labeled Fc variants are drawn to highlight the
spectral region corresponding to the anomeric region of the (1)GlcNAc residue.
The vertical dashed line corresponds to the 1H chemical shift of the upfield
signal in the Fc WT protein with a complex-type N-glycan. A complete spec-
trum of the Fc samples is shown in Figure S6.(Barb et al., 2009, 2012; Barb and Prestegard, 2011; Subedi
et al., 2014).
Motion of the N-glycan termini can be measured by solution
NMR spectroscopy. Previous studies reported a strong correla-
tion between the position of peaks in 2DNMR spectra of terminal
galactose residues and motion of the N-glycan termini (Barb
et al., 2012; Barb and Prestegard, 2011; Subedi et al., 2014).
The resonance frequency of the (60)galactose 13C2 nuclei repre-
sent a population-weighted average of the resonance fre-
quencies of two distinct states: the predominant state A with
the N-glycan terminus free from restriction, and state B
characterized by a direct interaction between the (60)galactose
residue and K246 side chain (Barb and Prestegard, 2011). The
(6)galactose residue undergoes a similar change in states, but
does not appear to directly contact the Fc polypeptide surface
(Subedi et al., 2014). Thus, the more populated the unrestricted
A state, the closer the observed resonance frequency is to theStructure 23, 1573–15frequency of the same nucleus in an unrestricted N-glycan
(labeled e in Figure 7).
A 1H-13C-HSQC spectrum of (13C2-galactose-labeled)-Fc
D265A, after enzymatic remodeling to the homogeneous glyco-
form in Figure 1B, is remarkably similar to a spectrum of (13C2-
galactose)-Fc WT, as shown in Figure 7. The spectrum of Fc
D265A shows minimal displacement toward the exposed state
of the N-glycan, and a small increase in an unrestricted form
(labeled e in Figure 7). Based on previous results (Subedi et al.,
2014), the displacement observed here indicates a small in-
crease in the mobility of the N-glycan termini, and is consistent
with the relatively small shift in glycan distribution noted at
the beginning of this subsection. This result is remarkable
because it indicates that the interaction between the N-glycan
termini and polypeptide is only marginally perturbed by the
D265A mutation; the primary perturbation due to the D265A
substitution is restricted to the C0E loop and is not largely
transmitted along the length of the N-glycan to the branch
termini. Thus, contacts proximal to the C0E loop contribute
more to structural stabilization of the polypeptide conformation,
and FcgRIIIa affinity, than distal interactions between the
N-glycan and polypeptide residues. Our observation is consis-
tent with a published report on a different glycoprotein, CD2,
indicating that two-thirds of the stabilizing effect of an N-glycan
on the underlying polypeptide is contributed by the (1)GlcNAc
residue, and the remainder by the more distal residues (Hanson
et al., 2009).
DISCUSSION
We previously reported that the intramolecular interface be-
tween the Fc N-glycan and polypeptide surface acts tomodulate
FcgRIIIa affinity through allostery; however, the mechanism
behind this allosteric modulation of FcgRIIIa affinity was not
defined (Subedi et al., 2014). The data presented herein clearly
define the relationship between the structure and function of
Fc N-glycosylation. Based on these results, the primary role
of the IgG1 Fc N-glycan is to stabilize the C0E loop through intra-
molecular interactions between carbohydrate and amino acid83, September 1, 2015 ª2015 Elsevier Ltd All rights reserved 1579
Figure 8. A Comprehensive Model of Fc Conformations
The Fc N-glycan is required to restrict the C0E loop, and state (iv) represents
the dominant conformation of FcWT that is also predisposed to bind FcgRIIIa.
The equilibrium established between states (iii) and (iv) can be perturbed by
removing the N-glycan or perturbing the N-glycan interface. For complete
exposure of the N-glycan, known to occur based on the sensitivity to glycan-
modifying enzymes that bind carbohydrate motifs consisting of 6+ residues,
the Cg2 reorients to allow for complete dissociation of the N-glycan from the
polypeptide surface and the Fc interstitial space.residues and, as a result, preorganize the FcgRIIIa interface for
optimal binding affinity.
The evidence supporting this conclusion includes solution-
based studies of the Fc T299A and Fc D265A variants that reveal
structural perturbations restricted to the C0E loop (Figures 3, 4,
and 5). With Fc T299A, we found no difference in Fc quaternary
structure upon comparison with Fc WT by measuring relative
Cg2/Cg3 domain orientation (Figure 2). Furthermore, the C0E
loop conformation shows a strong correlation with FcgRIIIa affin-
ity as measured through Y300 using Fc glycan and polypeptide
variants (Figure 5). These data, combined with measurements
of the N-glycan (Figures 6 and 7), indicate that the N-glycan
does not directly stabilize the optimal Cg2 orientation for
FcgRIIIa binding. A previous report implicates residues in the1580 Structure 23, 1573–1583, September 1, 2015 ª2015 Elsevier Lthinge region and at the Cg2/Cg3 domain interface as critical
for determining Cg2 orientation (Frank et al., 2014).
We developed a model of Fc conformational states that incor-
porates the diversity of in vitro enzyme-catalyzed modification
results, and solution- and solid-state structural data (Figure 8).
As determined in the Results, the predominant solution confor-
mation of Fc with a complex-type biantennary N-glycan is well
represented by one structure from X-ray crystallography
(1L6X), and is shown as state (iv). This form is primed for FcgRIIIa
binding, upon which minor conformational adjustments may
occur to form state (v), a complex with FcgRIIIa.
At the other extreme, Fc samples conformations that are not
suitable for binding. It is known from a wealth of reports that
the Fc N-glycan is fully exposed for modification by glycan-
modifying enzymes (Barb et al., 2012; Barb and Prestegard,
2011; Kobata, 2008; Raju, 2008; Subedi et al., 2014; Yu et al.,
2013). Two steps must occur before the N-glycan can become
exposed if the dominant state is represented by (iv). First, the
N-glycan must detach from the surface of the protein. It was
previously shown that the N-glycan termini are continuously
exchanging between unrestricted and peptide bound forms
(Barb and Prestegard, 2011). Extensive 200-ns all-atom compu-
tational simulations indicate that exchange of the glycan termini
is largely a local event limited to a few angstroms of deviation
(Frank et al., 2014). This event alone is likely insufficient to fully
expose the N-glycans for enzymatic modification. Second, it is
likely theCg2 domains reorient to allow theN-glycans to become
fully exposed. The wealth of Fc models point to a twisting motion
of the Cg2 domain, although one model for a more dramatically
altered conformation is proposed (Crispin et al., 2009).
Based on our analysis of Fc D265A, C0E loop deformation
likely precedes N-glycan exposure. This is supported by the con-
tact maintained between the Fc D265A N-glycan termini and
polypeptide interface (Figure 7). On the other hand, one would
expect a fully exposed Fc D265A N-glycan if N-glycan exposure
precedes C0E loop deformation. We observed restriction, rather
than complete exposure (Figure 7). Furthermore, it appears that
conformational states with altered C0E loop conformation have
preserved Cg2 domain orientation (Figures 2, 3, 4, and 5). The
most likely pathway from state (iv) to state (i) (with a fully exposed
N-glycan) goes through state (iii) with a disordered C0E loop, fol-
lowed by Cg2 reorientation (represented by (ii)). It is also possible
that the order of these two events is reversed, as indicated by the
alternate (iv)-(vi)-(ii)-(i) pathway.
The predominant contribution of C0E loop conformation to
FcgRIIIa affinity, and likely ADCC, highlights a pathway for rational
mAb improvement. Protein engineering to stabilize theC0E loop in
the conformation observed in Fc:FcgRIIIa complexes and inde-
pendent of glycosylation would benefit efficacy and reduce pro-
duction costs if the N-glycan could be avoided entirely. These
benefits are possible because the N-glycan exerts only an allo-
steric effect and is not known to directly contact receptors, if the
designs prove to be tolerated by the immune system of patients.EXPERIMENTAL PROCEDURES
Materials
Materials were purchased from Sigma-Aldrich, unless otherwise noted. Fc WT
and Fc polypeptide variants were prepared as previously described, as well asd All rights reserved
all Fc glycovariants (Subedi et al., 2014), unless otherwise noted. All methods,
including glycan analysis by matrix-assisted laser desorption/ionization mass
spectrometry, were conducted as described by Subedi et al. (2014) unless
otherwise noted.
Protein Expression
Human IgG1-Fc (residues 216–447) was largely prepared as described by
Subedi et al. (2014) with a 25-residue trypanosome signal peptide (Vander-
sall-Nairn et al., 1998) appended to the N terminus cloned into the NotI and
HindIIII sites of the pGen2 vector (Barb et al., 2012). Plasmids encoding
IgG1 Fc mutations were made according to the QuikChange method (Agilent
Technologies). All mutations were confirmed by DNA sequencing (ISU DNA
Facility). The extracellular region of FcgRIIIa (residues 19–193, V158 allotype)
containing N-terminal 83 histidine and GFP tags and a tobacco etch virus pro-
tease digestion site was cloned into the EcoRI and HindIII sites of the pGen2
vector (Barb et al., 2012) and expressed according to previously described
conditions (Subedi et al., 2014).
Isotope-Enriched Fc Samples
[15N-Y/K] FcwaspreparedasdescribedbySubedi et al. (2014) except for useof
custom FreeStyle293 expression medium (lacking tyrosine, lysine, or phenylal-
anine) supplementedwith [15N]L-tyrosine, [15N]L-lysine, andunlabeled L-phenyl-
alanine at 100 mg/l. 13CU labeling of Fc glycans was achieved by using [
13CU]
glucose as a metabolic precursor (Yamaguchi et al., 1998). Cells were trans-
fected, diluted, and cultured in FreeStyle293 medium as described by Subedi
et al. (2014) except that themediumwassupplementedwith3g/l [13CU]glucose.
NMR Spectroscopy
NMR measurements were collected at 37–50C using use either a 700-MHz
Bruker Avance II spectrometer or an 800-MHz Bruker Avance III spectrometer,
both equipped with a 5-mm cryogenically cooled probe. RDC measurements
were performed using [15N]Tyr/Lys labeled IgG1 Fc samples. NMR samples
were prepared in 20 mM MOPS (pH 7.4), 100 mM NaCl in a 10% D2O buffer.
IgG1 Fc samples for anisotropic measurements were prepared by adding Pf1
phage (ASLA Biotech) at a final concentration of 6–12 mg/ml in 210 ml with Fc
protein up to 0.3–0.4 mM (dimer). NMR samples with Pf1 phage were mixed
thoroughly and degassed by incubation at 50C before transfer to a 4-mmShi-
gemi NMR tube. The 2H splitting in the phage-included sample was observed
between 4 and 10 Hz.
Isotropic (1JNH) and anisotropic (
1JNH +
1DNH) couplings to measure N-H
bond RDCs was observed using an HSQC-TROSY-based J-modulated pulse
sequence (Liu and Prestegard, 2009). The modulation delays were 0.5, 1.0,
1.75, 3.5, 5.0, 6.5, 7.5 and 10.0 ms. The number of scans used was between
48 and 80 with free induction decay size of 2,048 points (1H) 3 96 points
(15N). The isotropic and anisotropic measurements for each sample took
approximately 24 and 32 hr, respectively. Spectra were processed using
NMRpipe (Delaglio et al., 1995). Peak intensities were measured and J-modu-
lation values fitted using NMRViewJ (OneMoon Scientific). RDCswere used to
calculate orientation tensors and Q values using PALES (Zweckstetter and
Bax, 2000). Hydrogen atoms were added to Fc structures from the PDB (Ber-
man et al., 2002) using REDUCE (Word et al., 1999).
NMRmeasurements of amide 15N R1 and R2 relaxation rates were collected
on the 800-MHz spectrometer using HSQC-TROSY-based methods available
in theBruker TopSpin 3.2 software package and analyzed usingNMRViewJ.R1
measurements were collected using eight different relaxation delay periods
(0.2, 0.4, 0.75, 1.0, 1.25, 1.5, 2.25, and 3 s) with a minimum delay of 4.8–2 s be-
tween scans.R2measurementswere collected using seven different relaxation
delay periods (4, 8, 12, 16, 20, 24, and 28ms)with a delay of 2 s between scans.
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